Access the full text.
Sign up today, get DeepDyve free for 14 days.
Purpose of ReviewWe review the management for unaffected BRCA1/2 mutation carriers and the local management of early-stage breast cancer.Recent FindingsFor unaffected BRCA1/2 mutation carriers, surveillance includes annual magnetic resonance imaging (MRI) and mammogram (MG). Novel imaging modalities, including abbreviated protocol MRI, ultrafast/accelerated MRI, and contrast-enhanced digital mammography are being investigated. Risk-reducing mastectomy (RRM) should be considered, and nipple-areolar sparing mastectomy (NSM) is now an option. Additionally, risk-reducing salpingo-oophorectomy (RRSO) is strongly recommended as it reduces mortality. In BRCA1/2 mutation carriers with breast cancer, BCT is an appropriate treatment option but to reduce risk of second primary, mastectomy and contralateral risk-reducing mastectomy should be considered.SummaryBreast and ovarian cancer screening and prevention options result in improved outcomes and decreased mortality in BRCA1/2 mutation carriers. In women with BRCA1/2 mutations who have BC, local management of the BC and secondary surgical prevention measures are different than women with sporadic disease.
Current Breast Cancer Reports – Springer Journals
Published: Jun 17, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.